Back to top
more

Syndax Pharmaceuticals (SNDX)

(Real Time Quote from BATS)

$21.13 USD

21.13
2,694,317

+1.44 (7.31%)

Updated Nov 6, 2024 02:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Syndax (SNDX) delivered earnings and revenue surprises of 13.27% and 96.85%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Incyte Announces Promising New Data on Oncology Candidate at ESMO

by Zacks Equity Research

INCY's INCB123667 data show the candidate's potential as a differentiated treatment option for cancers with increased cyclin E1 activity, amplification and/or overexpression in cells predictive of CDK2 dependency.

Incyte (INCY) Announces Data on Monjuvi, FDA Approval for GVHD Drug

by Zacks Equity Research

Incyte???s (INCY) late-stage study on tafasitamab for patients with relapsed or refractory follicular lymphoma meets its goal. FDA approves axatilimab for the treatment of chronic graft-versus-host disease.

Wall Street Analysts Think Syndax (SNDX) Could Surge 50.26%: Read This Before Placing a Bet

by Zacks Equity Research

The consensus price target hints at a 50.3% upside potential for Syndax (SNDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Regeneron (REGN) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when Regeneron (REGN) reports second-quarter 2024 results.

Wall Street Analysts Believe Syndax (SNDX) Could Rally 67.11%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 67.1% in Syndax (SNDX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Incyte's (INCY) Q1 Earnings & Revenues Fall Shy of Estimates

by Zacks Equity Research

Incyte's (INCY) first-quarter 2024 earnings and revenues miss estimates. The company maintains 2024 revenue guidance for its lead drug, Jakafi.

Syndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA

by Zacks Equity Research

Syndax Pharmaceuticals (SNDX) groundbreaking menin inhibitor, revumenib, receives FDA priority review for treating relapsed, refractory acute leukemia.

Syndax (SNDX) is on the Move, Here's Why the Trend Could be Sustainable

by Zacks Equity Research

Syndax (SNDX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Incyte's (INCY) Q4 Earnings & Revenues Fall Shy of Estimates

by Zacks Equity Research

Incyte's (INCY) fourth-quarter 2023 earnings and revenues miss estimates. Quarterly revenues cross the $1 billion mark for the first time on the continued growth of Jakafi and the strong launch of Opzelura.

Syndax Pharmaceuticals (SNDX) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, Syndax Pharmaceuticals (SNDX) closed at $20.10, marking a -0.94% move from the previous day.

Syndax Pharmaceuticals (SNDX) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Syndax Pharmaceuticals (SNDX) closed at $20.91 in the latest trading session, marking a -0.99% move from the prior day.

Syndax Pharmaceuticals (SNDX) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Syndax Pharmaceuticals (SNDX) closed the most recent trading day at $21.94, moving +1.72% from the previous trading session.

Syndax Pharmaceuticals (SNDX) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Syndax Pharmaceuticals (SNDX) closed at $23.07, marking a -0.26% move from the previous day.

Syndax Pharmaceuticals (SNDX) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Syndax Pharmaceuticals (SNDX) closed the most recent trading day at $22.30, moving -1.24% from the previous trading session.

Syndax Pharmaceuticals (SNDX) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Syndax Pharmaceuticals (SNDX) closed the most recent trading day at $22.58, moving +0.71% from the previous trading session.

Immunocore (IMCR) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On Immunocore's (IMCR) Q4 earnings call, investors will likely focus on the sales figure of Kimmtrak - its first-line treatment for metastatic uveal melanoma - and updates on its pipeline candidates.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Syndax Pharmaceuticals (SNDX) Stock Moves -1.99%: What You Should Know

by Zacks Equity Research

Syndax Pharmaceuticals (SNDX) closed at $25.64 in the latest trading session, marking a -1.99% move from the prior day.

Anika (ANIK) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On Anika Therapeutics' (ANIK) Q4 earnings call, investors are likely to focus on the sales performance of its Osteoarthritis Pain (OAP) Management, Joint Preservation and Restoration segments.

Syndax (SNDX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Devoid of marketed drugs, investors' focus will be on Syndax Pharmaceuticals' (SNDX) pipeline progress when it reports its fourth-quarter earnings.

Syndax Pharmaceuticals (SNDX) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Syndax Pharmaceuticals (SNDX) closed at $25.77, marking a +1.38% move from the previous day.

Acer (ACER) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On Acer Therapeutics' (ACER) fourth-quarter earnings call, investors' focus is likely to be on the company's pipeline development.

Novavax (NVAX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On Novavax's (NVAX) fourth-quarter earnings call, investors' focus is likely to be on the sales figures of its COVID-19 vaccine.

Regeneron's (REGN) Eylea Gets FDA Nod for ROP in Infants

by Zacks Equity Research

Regeneron's (REGN) Eylea gets FDA approval for the treatment of preterm infants with retinopathy of prematurity (ROP).